Crispr Therapeutics Ag (CRSP)
$65.36
0.67 (1.01%)
CRSP Stock Quote Delayed 15 Minutes
Previous Close
$65.36
Market Cap
3.06B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
739,800
Day's Range
64.35 - 67.37
52-Week Range
22.22 - 74.00
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
Consider Adding New Positions in U.S. Cannabis Stocks
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR Has the Potential to Cure Cancer and Make You Triple-Digit Gains
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Why NOW Is the Time to Buy Gene Therapy Stocks
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
Why CRSP Stock Has Added Layers of Risk
Even by biotech standards, CRSP stock is volatile and prone to snap reactions -- but the potential rewards are huge.
Gene Editing is a Major Technology to Watch
Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.
A Single Study Is No Reason to Sell Crispr Stock
Crispr stock is down 7% on the release of a new study. But the headline is not nearly as scary as it sounds.
After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall
Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.
5 Biotech Stocks to Boost Your Portfolio’s Health This Year
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio. Compare Brokers....
Does Crispr Therapeutics AG Deserve This Massive Rally?
Crispr stock is riding a euphoric wave thanks to the biotech firm’s innovations. But what is CRISPR and what are the downsides?
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
